Recursion agrees Phase 3 design with FDA for REC-4881 in familial adenomatous polyposis
The registrational trial of the oral MEK1/2 inhibitor will count removal of any adenoma of 10 mm or larger as an event and is planned to start in the second half of 2027; FAP has no FDA-approved drug.
Why it matters
Recursion is one of the best-known companies using AI to find and develop drugs, and a registrational trial design agreed with the FDA is a step toward testing whether such a programme can reach approval. The endpoint, event-free survival, also counts FAP-related surgery, high-grade dysplasia, cancer and death. Patients currently face lifelong endoscopic surveillance and repeated polyp removal. Watch enrolment of the planned trial once it opens in the second half of 2027.
Key facts
- REC-4881 is an oral MEK1/2 inhibitor
- For adults with FAP after colectomy or proctocolectomy
- Event: removal of an adenoma 10 mm or larger
- Primary endpoint: event-free survival
- Trial planned to start in the second half of 2027